Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Immunotherapy in Sarcomatoid Mesothelioma
NCT05647265Phase 2Recruiting
- Sponsor
- Cancer and Leukemia Group B
- Start
- Nov 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in pleural mesothelioma, sponsored by Cancer and Leukemia Group B. Started Nov 2024; status: recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on NCT05647265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05647265.